James obtained his undergraduate Biochemistry degree from the University of Manchester. During his studies, he was awarded a Pre-doctoral Fellowship enabling him to spend a year working in a research laboratory at Thomas Jefferson University in the USA, where he studied the effects of extracellular matrix proteins on tumour microenvironment signalling pathways.
James obtained a DPhil from the University of Oxford, during which he conducted research at the Ludwig Institute for Cancer Research. Through utilization of a broad array of next generation sequencing technologies, coupled to bioinformatics analyses, his work enabled an improved understanding of the mechanisms that underpin pan-genomic binding site selection of the hypoxia-inducible transcription factors. During his DPhil, James’ work contributed to numerous high-impact publications. He also presented at several international conferences, including a talk at the biennial Keystone Hypoxia Conference in British Columbia, Canada.
James joined J A Kemp as a trainee patent attorney in 2017.